AIG
SYRE icon

American International Group’s Spyre Therapeutics SYRE Stock Holding History

American International Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-803
Closed -$46K – 3257
2022
Q1 		$46K Sell
803
-56
-7% -$4.7K ﹤0.01% 2874
2021
Q4 		$102K Sell
859
-26
-3% -$4.1K ﹤0.01% 2708
2021
Q3 		$176K Sell
885
-21
-2% -$3.67K ﹤0.01% 2498
2021
Q2 		$158 Sell
906
-146
-14% -$26.5K ﹤0.01% 2652
2021
Q1 		$208 Buy
1,052
+2
+0.2% +$384 ﹤0.01% 2346
2020
Q4 		$207 Buy
1,050
+46
+5% +$9.53K ﹤0.01% 2272
2020
Q3 		$178K Sell
1,004
-23
-2% -$4.25K ﹤0.01% 2206
2020
Q2 		$238K Buy
1,027
+407
+66% +$77.5K ﹤0.01% 2025
2020
Q1 		$72K Sell
620
-35
-5% -$5.95K ﹤0.01% 2503
2019
Q4 		$125K Sell
655
-6
-0.9% -$1.18K ﹤0.01% 2495
2019
Q3 		$127K Sell
661
-4
-0.6% -$779 ﹤0.01% 2462
2019
Q2 		$114K Buy
665
+178
+37% +$30.8K ﹤0.01% 2605
2019
Q1 		$98K Buy
487
+53
+12% +$11K ﹤0.01% 2631
2018
Q4 		$81K Buy
434
+1
+0.2% +$212 ﹤0.01% 2699
2018
Q3 		$104K Buy
433
+8
+2% +$1.87K ﹤0.01% 2819
2018
Q2 		$112K Buy
+425
New +$105K ﹤0.01% 2720

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American International Group's SYRE Position: Q2 2022 in Review

American International Group sold out of Spyre Therapeutics (SYRE) in Q2 2022, closing a stake of 803 shares — an estimated $46K sold.

American International Group first reported a position in SYRE in Q2 2018 and held it in 16 quarters. The position peaked at $238K in Q2 2020. 66 funds tracked by Wall St. Rank hold SYRE as of Q2 2022.

  • American International Group reported no remaining Spyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 803 Spyre Therapeutics shares in Q2 2022, an estimated $46K.
  • American International Group first reported a position in Spyre Therapeutics in Q2 2018 and held it in 16 quarters.
  • American International Group's Spyre Therapeutics position peaked at $238K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.